Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has shared an update.
The Capital Group Companies, Inc., a major investment management company based in Los Angeles, has acquired a significant stake in AstraZeneca PLC, crossing a 5% threshold of voting rights on January 29, 2025. This acquisition highlights Capital Group’s strategic interest in AstraZeneca’s operations, potentially influencing the company’s future governance and strategic decisions.
More about AstraZeneca
AstraZeneca is a UK-based global pharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in areas such as oncology, cardiovascular, renal, and metabolism, as well as respiratory and immunology.
YTD Price Performance: 11.90%
Average Trading Volume: 2,726,647
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £181.6B
Learn more about AZN stock on TipRanks’ Stock Analysis page.